CTOs on the Move

Black Diamond Therapeutics

www.blackdiamondtherapeutics.com

 
Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Black Diamond Therapeutics raised $20M on 12/12/2018
Black Diamond Therapeutics raised $85M on 01/09/2019

Similar Companies

Laser Pharmceuticals

Laser Pharmceuticals is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canon Medical Systems

We want to share our innovations with you and learn from your feedback. Help us improve quality and design to make sure your system delivers from day one.

Newlink Genetics

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.

Diffusion Pharmaceuticals

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

TheraTrue

TheraTrue prides itself on its commitment to operating fully regulated, transparent, and highly professional facilities that will deliver vital products to improve the quality of life for patients suffering from debilitating medical conditions.